{"id":"NCT00658632","sponsor":"Eisai Inc.","briefTitle":"Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)","officialTitle":"A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-02","primaryCompletion":"2009-04","completion":"2009-09","firstPosted":"2008-04-15","resultsPosted":"2015-06-23","lastUpdate":"2016-05-04"},"enrollment":1397,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Gastroesophageal Reflux Disease (GERD)"],"interventions":[{"type":"DRUG","name":"Rabeprazole sodium","otherNames":["Aciphex"]},{"type":"DRUG","name":"Esomeprazole","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to investigate the efficacy and safety of Rabeprazole (RAB) Extended-Release (ER) 50 mg versus Esomeprazole (ESO) 40 mg in subjects with erosive gastroesophageal reflux disease (eGERD).","primaryOutcome":{"measure":"Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks","timeFrame":"Baseline and Week 8","effectByArm":[{"arm":"ESO 40 mg","deltaMin":87.8,"sd":null},{"arm":"RAB ER 50 mg","deltaMin":88.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":85,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":676},"commonTop":[]}}